Mannosylated Polycations Target CD206⁺ Antigen-Presenting Cells and Mediate T-Cell-Specific Activation in Cancer...

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Cancer immunotherapy faces challenges with limited response and tumor specificity.
• Targeting antigen-presenting cells (APCs) is crucial for effective vaccine delivery.
• Mannose receptor (CD206) is a potential target on APCs for enhanced cellular uptake.

Purpose of the Study:

• To develop mannosylated polycations as vectors for plasmid DNA (pDNA)-based cancer vaccines.
• To improve selective delivery of genetic material to APCs.
• To enhance immune cell activation and anti-tumor responses.

Main Methods:

• Synthesis of diblock and triblock glycopolycations using mannose (M), agmatine (A), and butyl (B) derivatives.
• Complexation of pDNA with glycopolycations at low N/P ratios (<5).
• In vitro assessment of dendritic cell activation and antigen presentation (SIINFEKL peptide via MHC-I).
• In vivo evaluation of T-cell response and tumor growth reduction in a B16-OVA melanoma model.

Main Results:

• Glycopolycations efficiently complexed pDNA, protecting it from degradation.
• Specific glycopolycations (M58A45, M62A52B32) activated dendritic cells and promoted SIINFEKL peptide presentation.
• Administration of M58A45/pOVA induced SIINFEKL-specific T-cell responses in mice.
• Significant reduction in tumor growth was observed in the B16-OVA melanoma model.

Conclusions:

• Mannosylation is an effective strategy for targeting immune cells in cancer vaccination.
• Developed glycopolycations show potential as efficient delivery vehicles for nucleic acid-based therapies.
• This approach enhances anti-tumor immunity and warrants further investigation for cancer treatment.